0.03Open0.03Pre Close0 Volume355 Open Interest25.00Strike Price0.00Turnover531.41%IV634.02%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0336Delta0.0250Gamma113.67Leverage Ratio-0.0101Theta0.0000Rho3.82Eff Leverage0.0004Vega
Revance Therapeutics Stock Discussion
Dow Jones· 1 min ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Monday, 6th January at 9:00 am
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories
GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ: RVNC) to acquire Revance for $3.60 per s...
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
No comment yet